# A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers

> **NCT06698861** · PHASE1 · COMPLETED · sponsor: **PharmaEssentia** · enrollment: 30 (actual)

## Conditions studied

- PK in Healthy Volunteers

## Interventions

- **DRUG:** PEG-MetHuG-CSF
- **DRUG:** Neulasta (Amgen)

## Key facts

- **NCT ID:** NCT06698861
- **Lead sponsor:** PharmaEssentia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-19
- **Primary completion:** 2025-02-06
- **Final completion:** 2025-02-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698861, "A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06698861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*